SCHEMBL2444829

SCHEMBL2444829

CCOC(=O)c1nnc(NC=O)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
AKT1 P31749 1/20 0.46
IRS1 P35568 1/20 0.46
GAB1 Q13480 1/20 0.46
GAA P10253 4/20 0.42
P2RY1 P47900 1/20 0.42
HPGD P15428 3/20 0.39
LMNA P02545 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
RECQL P46063 1/20 0.39
MAPT P10636 3/20 0.38
KDM4E B2RXH2 1/20 0.36
DHODH Q02127 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12852499 0.82 AKT1 (0.51) ALDH1A1SMN1; SMN2AKT1IRS1GAB1
SCHEMBL20888432 0.81 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2AKT1IRS1GAB1
SCHEMBL12464192 0.79 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2AKT1IRS1GAB1
SCHEMBL14864429 0.78 AKT1 (0.65) ALDH1A1SMN1; SMN2AKT1IRS1GAB1
SCHEMBL2444824 0.78 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2AKT1IRS1GAB1
SCHEMBL2442388 0.78 SMN1; SMN2 (0.41) ALDH1A1SMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL4315953 0.74 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2AKT1IRS1GAB1
SCHEMBL299130 0.74 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2AKT1IRS1GAB1
SCHEMBL23742047 0.74 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2GAAHPGDLMNA
SCHEMBL31052510 0.72 P2RY1 (0.42) ALDH1A1SMN1; SMN2AKT1IRS1GAB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120107273-A1 NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-05-03 US disclosed
US-8017612-B2 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors JAPAN TOBACCO INC. (JP) 2011-09-13 US disclosed
EP-2009004-A1 NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR Japan Tobacco, Inc. (JP) 2008-12-31 EP disclosed
US-20080081818-A1 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors JAPAN TOBACCO INC. (JP) 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081818-A1 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors HAVCR2, AADAC, DNPEP ALDH1A1 96/4885SMN1; SMN2 4462/4885AKT1 4435/4885
US-20120107273-A1 NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR POLR1C, POLR2E, POLR2H ALDH1A1 557/4885SMN1; SMN2 4299/4885AKT1 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.